| Type | Public |
|---|---|
| Traded as | NASDAQ: ONXX: [1]) |
| Industry | Biotechnology |
| Founded | 1992 |
| Headquarters | South San Francisco California U.S. |
| Key people | N. Anthony (Tony) Coles (CEO) |
| Products | Sorafenib (Nexavar) |
| Employees | 375 |
| Website | www.onyx-pharm.com |
Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) is a biopharmaceutical company headquartered in South San Francisco, California. The company develops and markets medicines for the treatment of cancer. Onyx was founded in 1992 by Frank McCormick Ph.D., FRS.[1] In 2009, the company acquired Proteolix, Inc., a private biotechnology company.
Contents |
Sorafenib (co-developed and co-marketed by Bayer and Onyx as Nexavar[2]), is a drug approved for the treatment of advanced renal cell carcinoma, or advanced kidney cancer, and for the treatment of hepatocellular carcinoma, the most common form of liver cancer[3]. Sorafenib is also being evaluated in additional types of cancer, including lung[4][5], thyroid[6] and breast cancers[7].
As of September 2011, Onyx is conducting clinical trials investigating carfilzomib, a selective proteasome inhibitor that is being studied as a treatment for multiple myeloma. Clinical trials for carfilzomib include a pivotal Phase 2 clinical trial designed to seek accelerated approval in the U.S. In January 2011, the U.S. Food and Drug Administration (FDA) granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application for carfilzomib [8].